- Home
- WATT vs CHRO Comparison
WATT vs CHRO Comparison
Compare WATT & CHRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WATT
- CHRO
- Stock Information
- Founded
- WATT 2012
- CHRO 2002
- Country
- WATT United States
- CHRO United States
- Employees
- WATT N/A
- CHRO N/A
- Industry
- WATT Radio And Television Broadcasting And Communications Equipment
- CHRO
- Sector
- WATT Technology
- CHRO
- Exchange
- WATT Nasdaq
- CHRO Nasdaq
- Market Cap
- WATT 9.1M
- CHRO 8.4M
- IPO Year
- WATT 2014
- CHRO 2024
- Fundamental
- Price
- WATT $0.28
- CHRO $0.93
- Analyst Decision
- WATT
- CHRO Strong Buy
- Analyst Count
- WATT 0
- CHRO 1
- Target Price
- WATT N/A
- CHRO N/A
- AVG Volume (30 Days)
- WATT 2.0M
- CHRO 84.7K
- Earning Date
- WATT 05-13-2025
- CHRO 05-13-2025
- Dividend Yield
- WATT N/A
- CHRO N/A
- EPS Growth
- WATT N/A
- CHRO N/A
- EPS
- WATT N/A
- CHRO N/A
- Revenue
- WATT $1,047,000.00
- CHRO N/A
- Revenue This Year
- WATT $1,028.91
- CHRO N/A
- Revenue Next Year
- WATT N/A
- CHRO N/A
- P/E Ratio
- WATT N/A
- CHRO N/A
- Revenue Growth
- WATT 137.41
- CHRO N/A
- 52 Week Low
- WATT $0.12
- CHRO $0.45
- 52 Week High
- WATT $2.70
- CHRO $3.80
- Technical
- Relative Strength Index (RSI)
- WATT 50.45
- CHRO 34.93
- Support Level
- WATT $0.27
- CHRO $0.92
- Resistance Level
- WATT $0.29
- CHRO $1.05
- Average True Range (ATR)
- WATT 0.02
- CHRO 0.10
- MACD
- WATT 0.00
- CHRO 0.00
- Stochastic Oscillator
- WATT 40.25
- CHRO 6.58
About WATT Energous Corporation
Energous Corp has developed wireless power networks technology (WPNT), consisting of semiconductor chipsets, software controls, hardware designs and antennas, that enable radio frequency (RF) based charging for Internet of Things (IoT) devices. Its products include Transmitter IC & Module, Receivers IC, Transmitter System and other tools.
About CHRO Chromocell Therapeutics Corporation
Channel Therapeutics Corp is a clinical-stage biotechnology company developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic, visceral pain, acute and chronic eye pain, and post-surgical nerve blocks. Its pipeline includes CC8464 for ISFN and EM and CT2000 for Acute and CHronic Eye Pain-Dry Eye Disease.